Vera Therapeutics, Inc. Stock News

Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Im

The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today.

The biotech added two new executives to its ranks. Both have considerable experience in healthcare industry management.

Vera Therapeutics is a clinical stage company that some analysts think could be worth $1 billion. The company could have an approved product for the treatment of IgA nephropathy by 2026.

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme

The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St

Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys

Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum

Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vera Therapeutics revealed 36-week efficacy and safety findings of its Phase IIb ORIGIN clinical study of atacicept for IgAN at the 60th European Renal Association Congress. The study met its primary

Vera Therapeutics, Inc. is trying to develop an old molecule it licensed from Merck & Co., Inc. Trials conducted years earlier produced unimpressive results. While the company has produced some positi

The company's lead therapy, Atacicept, is faring well in a phase 2b trial. Vera Therapeutics is already recruiting patients for a phase 3 trial for Atacicept.

Vera Therapeutics, Inc shares climbed 20% to $15.38 on Tuesday after the late-stage biotechnology company revealed positive trial results for atacicept, its treatment for an autoimmune disease of the

Shares of two biotech stocks are way up over the past month thanks to impressive clinical trial results for the drugs they're developing. Chinook Therapeutics has agreed to a buyout offer from Merck b